Nearly one-quarter of children in remission from ALL miss doses of maintenance medication

the ONA take:

Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk. Adherence is lowest in African American (46%) and Asian (28%) children, compared with non-Hispanic white children (14%). Children who came from household in which their mother acted as full-time caregiver and medication supervisor had better adherence. Relatively low level of education in the mother as well as single-parent, multiple-children households were factors in nonadherence among African American children. Coming from a low-income household was a factor among Asian children. Nonadherence was lower in non-Hispanic children whose fathers had a low education level. However, regardless of race, forgetfulness was the most common reason reported for children not taking their 6MP medication.

Nearly one-quarter of children in remission from ALL miss doses of maintenance medication
Nearly one-quarter of children in remission from ALL miss doses of maintenance medication
An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published online in Blood, the Journal of the American Society of Hematology.
READ FULL ARTICLE From Medical News Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs